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A B S T R A C T
The authors describe a usual case of inﬁltrative low-grade glial neoplasm with a marked enhanced area which is diﬃcult to diagnose. A 42-year-old man had the
diﬀuse mass lesion partially with apparent enhancement in the right temporal lobe, the insular, and the basal ganglia regions. Final pathological diagnosis from the
removed specimens was IDH-wildtype diﬀuse astrocytoma according to 2016 WHO classiﬁcation, although it had unusual ﬁndings including gliomesenchymal re-
action. The nodule-like enhancement was thought to be owing to the mesenchymal component. Several molecular analysis including pyrosequence analysis, Ion
Torrent™ next-generation sequencing and multiplex ligation-dependent probe ampliﬁcation analysis detected no genomic abnormality. IDH-wildtype diﬀuse astro-
cytoma is a heterogeneous category and has a minor subset with a silent genomic landscape like the present case.
1. Introduction
A diﬀuse astrocytoma is a diﬀusely inﬁltrative glial tumor occurring
at the peak from 30 to 50 years old as the typical age of its diagnosis
and mainly locates in the cerebral hemisphere [1]. A magnetic re-
sonance imaging (MRI) of the typical diﬀuse astrocytoma shows hyper-
intensity on T2WI and no (or minimal) enhancement by the contrast
medium. In a previous paper, only 50 cases (5.4%) of 927 WHO grade II
gliomas had nodule-like enhancement pattern [2]. In this report, we
describe a case of diﬀuse astrocytoma with a marked enhanced area
which is diﬃcult to diagnose before surgery.
2. Case presentation
A 42-year-old man was referred to our hospital because of mild
paralysis of the left leg. Six month ago he also developed left upper limb
paralysis. MRI showed the lesion was hypo-intense on T1- weighted
images (WI), of mixed intensity on T2WI, and hypo-intense on diﬀu-
sion-WI (DWI) in the right temporal lobe, the insular, and the basal
ganglia regions (Fig. 1). A part of the lesion had large nodule-like en-
hancement after the gadolinium (Gd) injection, and showed hypo-per-
fusion at the cerebral blood volume study. The patient underwent lesion
biopsy for pathological diagnosis. Pathological diagnosis from the
biopsy specimen was not classiﬁed according to any existing classiﬁ-
cation and seemed to show a low-grade neoplasm. Both neurological
ﬁndings, including the paralysis and neuroimaging data improved in-
tensely after oral and intravenous corticosteroids for relieving peritu-
moral edema (Fig. 2). Despite recommendation of treatment with
radiotherapy and/or temozolomide (TMZ) the patient refused any
chemo-radiotherapy.
Ten months after the ﬁrst surgery, the left paresis worsened and MRI
showed the increasing tumor in the temporal lobe extending to the
frontal lobe (Fig. 2). He underwent partial tumor removal. Pathological
diagnosis from the specimen was basically the same as after the ﬁrst
surgery. An inﬁltrative neoplasm mainly consisted of astrocytic tumor
cells (Fig. 3), positive for glial ﬁbrillary acidic protein (GFAP). Neither
piloid tumor cell nor degenerative structure such as rosenthal ﬁber and
eosinophilic granular body were shown in the specimen. Additionaly, in
the Gd-enhanced area mainly located in the insular cortex, there were
spindle-shaped cells near the astrocytic tumor cells, that were positive
for reticulin, indicating mesenchymal cells (Fig. 4).
Immunohistochemical staining of synaptophysin, neuroﬁlament,
CD34 and Neu-N as neuronal markers showed that they were stained
mainly in normal neurons of the gray matter (Figs. 4 and 5). Any part of
specimens did not show accumulation of macrophages or perivascular
lymphocytic cuﬃng such as demyelinating disease. Final pathological
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diagnosis was IDH-wildtype diﬀuse astrocytoma according to 2016 WHO
classiﬁcation, although it had unusual ﬁndings including gliome-
senchymal reaction. The patient received fractionated radiotherapy
(FRT, 61.2Gy/34fr) concomitant with TMZ after the second surgery. As
he developed drug eruption on his precordia, legs, so he stopped taking
oral drugs including TMZ. Four months after completion of FRT, he
restarted maintenance TMZ treatment. Since pyrosequence analysis of
the specimen showed wild type of IDH-1/2 R132/R172, BRAF T599/
V600, H3F3A K27/G34, TERT C250/C228 genes and the hypo-methy-
lated (unmethylated) MGMT CpG island, the TMZ was stopped after
ﬁnishing the 2nd cycle of administration. Ion Torrent™ next-generation
sequencing also showed no mutational status of BRAF, RB1, TP53 and
ATRX in tumor tissue. Multiplex ligation-dependent probe ampliﬁca-
tion analysis did not detect 1p19 co-deletion, 10q loss (PTEN), 7p
ampliﬁcation (EGFR) or 9p homozygous deletion (CDKN2A). Tumor
recurrence was not seen in the patient 24months after the 1st surgery.
Fig. 1. The axial view of magnetic resonance images (MRI) on admission. An area from right temporal region to insula on T2WI, T1WI and T1WI with gadolinium
(Gd) enhancement (upper), and MR spectroscopy, diﬀusion WI, perfusion image, and the coronal view of FLAIR image (lower) is shown.
Fig. 2. The axial view of MRI (upper and upper middle, T1WI with Gd enhancement; lower and lower middle, T2WI) before and after the biopsy, partial removal (PR)
and radiation therapy (RT) concomitant with temozolomide (TMZ) showing the drastic change of tumor lesion.
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Fig. 3. T1WI with Gd enhancement before and just after partial resection of lesion (A), macroscopic image (B) and histopathological images (C–E). C. A histo-
pathological image (Hematoxylin-Eosin (HE) staining (magniﬁcation, ×1.25)). D. Inﬁltrative glial cell-rich area and mesenchymal cell-rich area (HE staining and
GFAP staining (magniﬁcation, ×100)); E. HE, IDH-R132H, Olig2, p53, ATRX, and MIB-1 staining of inﬁltrative glial cell-rich area (magniﬁcation, ×400).
Fig. 4. A. Histopathological images of mesenchymal cell-rich area (HE staining (magniﬁcation, ×200); GFAP, S-100 protein and vimentin staining (magniﬁcation,
×400)). B. The area is positive for reticulin staining and negative for Elastic van Gieson (EVG) staining (magniﬁcation, ×200). C. Neuroﬁlament (NF) stain shows
diﬀuse axons and neurons in any part of the tumor tissue (magniﬁcation, ×200).
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3. Discussion
The supratentorial lesion in the present case is a very rare case of
diﬀuse astrocytoma with a nodule-like component. Furthermore ster-
oids were eﬀective for regression of T2 high-intensity area. It may be
related to peritumoral edema due to mesenchymal component in these
astrocytic tumors. A review of previous reports shows that there is a
category named ‘glioﬁbroma’ or ‘desmo-plastic glioma’ that co-existing
malignant glia cells and benign mesenchymal cells [3], categorized as a
so-called ‘gliomesenchymal tumor’ [4], although these mixed type tu-
mors are not oﬃcially categorized in 2016 WHO classiﬁcation [5]. In
the present case, however, the lesion might not be glioﬁbroma, since
mesenchymal cells positive for reticulin staining were only around the
inﬂammatory vessels in the cortex, indicating secondary changes by the
inﬂammation of vessels but not produced by the tumor. Pleomorphic
xanthoastrocytoma, which is another type of astrocytic tumor and has a
typical superﬁcial location in the cerebral hemisphere, often has the
reticulin ﬁbers as a reactive change [6].
In general, IDH-wildtype diﬀuse astrocytoma has poorer prognosis
compared to other types of lower grade gliomas [7]. In addition, no-
dule-like enhancement pattern is also a risk factor of poorer prognosis
in WHO grade II gliomas [2]. However, in more recent paper, adult
IDH-wildtype diﬀuse gliomas is prognostically heterogeneous category
[8, 9], and has a minor subset with a silent genomic landscape like a
pilocytic astrocytoma and favorable prognosis relative to others [8].
TERT promotor mutation, EGFR ampliﬁcation and H3F3A mutation
were associated with poor prognosis, and lacking all of the 3 genomic
abnormality was associated with good prognosis in IDH-wildtype diﬀuse
astrocytoma [9]. Because the tumor in the present case lacks all of the 3
genomic abnormality, it may belong to the good prognosis group de-
spite having a nodule-like enhancement. In a limitation of this mole-
cular analysis, there is a possibility that the evaluated tissue was not
fully representative as only homogenized tissue was studied that lacks
morphological control.
In conclusions, we have experienced treating a unique inﬁltrative
low-grade glial neoplasm with gliomesenchymal reactions
pathologically and with a nodule-like enhancement on MRI, which was
diagnosed as an IDH-wildtype diﬀuse astrocytoma according to the 2016
WHO classiﬁcation. The clinical course of this tumor and neuroimaging
results were unusual for typical diﬀuse astrocytoma.
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Fig. 5. Histopathological images of inﬁltrative glial cell-rich and mesenchymal cell-rich areas (HE and CD34 staining (magniﬁcation, ×200)).
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